58476-59-8

Basic information

• Product Name: N-(4-broMophenyl)-2-nitrobenzenaMine
• Synonyms: N-(4-broMophenyl)-2-nitrobenzenaMine;(4-BroMo-phenyl)-(2-nitro-phenyl)-aMine
• CAS NO: 58476-59-8
• Molecular Formula: C₁₂H₉BrN₂O₂
• Molecular Weight: 293.11606
• Mol File: 58476-59-8.mol
• Article Data: 38

Chemical Properties

• Melting Point: 162 °C
• Boiling Point: 393.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.597±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -4.06±0.40(Predicted)
• CAS DataBase Reference: N-(4-broMophenyl)-2-nitrobenzenaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-broMophenyl)-2-nitrobenzenaMine(58476-59-8)
• EPA Substance Registry System: N-(4-broMophenyl)-2-nitrobenzenaMine(58476-59-8)

Safety Data

• Hazardous Substances Data: 58476-59-8(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthesis, p. 430, 1990 DOI: 10.1055/s-1990-26897

Upstream product

• 88-73-3 2-Chloronitrobenzene 
• 106-40-1 4-bromo-aniline 
• 106-37-6 1.4-dibromobenzene 
• 88-74-4 2-nitro-aniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 589-87-7 1,4-bromoiodobenzene 
• 577-19-5 2-nitrophenyl bromide 

Downstream Products

• 100953-52-4 N¹-(4-bromophenyl)benzene -1,2 -diamine 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 857440-01-8 N-(4-Bromo-phenyl)-N-methyl-benzene-1,2-diamine 
• 1027173-03-0 4-(2-Bromo-5-methyl-5H-dibenzo[b,e][1,4]diazepin-11-yl)-benzoic acid methyl ester 
• 1027985-23-4 N-{2-[(4-Bromo-phenyl)-methyl-amino]-phenyl}-terephthalamic acid methyl ester 
• 3331-28-0 2-bromophenazine 
• 760212-57-5 N-[2-(4-bromophenyl amino) phenyl] benzamide 
• 1221892-57-4 C₁₉H₁₄BrN₃O 
• 1352872-60-6 4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-biphen-2-ylamine 
• 1352872-61-7 N-{4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-biphenyl-2-yl}-3-cyano-benzamide 
• 1352872-84-4 N-{4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-4-methyl-biphenyl-2-yl}-acetamide trifluoroacetic acid 
• 1352874-51-1 4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-4-methyl-biphenyl-2-ylamine trifluoroacetic acid 
• 1352872-85-5 2-Amino-N-{4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-biphenyl-2-yl}-acetamide 
• 1352872-96-8 4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-5-fluoro-biphenyl-2-ylamine 

Relevant articles and documents

Benzimidazolone derivatives organic light emitting compound and organic electroluminescent device including the same

Provided is a benzo imidazolone derivative organic electroluminescent compound represented by chemical formula a. Chemical Formula a. The benzo imidazolone derivative organic light emitting compound is suitable for inclusion in an organic electroluminescent device. Both electrochemical stability and thermal stability can be satisfactorily met.

A green and practical reduction of N-(4-chlorophenyl)-2-nitroaniline and its derivatives to corresponding N-substituted-benzene-1,2-diamines using thiourea dioxide

A new effective approach for synthesizing diverse N-substituted-benzene-1,2-diamines is reported. The treatment of N-substituted-2-nitroanilines with thiourea dioxide in the presence of sodium hydroxide efficiently formed the corresponding N-substituted-benzene-1,2-diamines, including N-(4-chlorophenyl)benzene-1,2-diamine with a good yield of 94%. The by-product is environmentally-friendly urea and is easy to separate from the product by filtration procedure that enhances the convenience of the approach.

Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors

Blocking c-Met kinase activity by small-molecule inhibitors has been identified as a promising approach for the treatment of cancers. Herein, we described the design, synthesis, and biological evaluation of a series of 4-phenoxypyridine-based 3-oxo-3,4-dihydroquinoxaline derivatives as c-Met kinase inhibitors. Inhibitory activitives against c-Met kinase evaluation indicated that most of compounds showed excellent c-Met kinase activity in vitro, and IC50 values of ten compounds (23a, 23e, 23f, 23l, 23r, 23s, 23v, 23w, 23x and 23y) were less than 10.00 nM. Notably, three of them (23v, 23w and 23y) showed remarkable potency with IC50 values of 2.31 nM, 1.91 nM and 2.44 nM, respectively, and thus they were more potent than positive control drug foretinib (c-Met, IC50 = 2.53 nM). Cytotoxic evaluation indicated the most promising compound 23w showed remarkable cytotoxicity against A549, H460 and HT-29 cell lines with IC50 values of 1.57 μM, 0.94 μM and 0.65 μM, respectively. Furthermore, the acridine orange/ethidium bromide (AO/EB) staining, cell apoptosis assays by flow cytometry, wound-healing assays and transwell migration assays on HT-29 and/or A549 cells of 23w were performed. Especially compound 23w, which displayed potent antitumor, apoptosis induction and antimetastatic activity, could be used as a promising lead for further development. Meanwhile, their preliminary structure-activity relationships (SARs) were also discussed.